Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.78 |
| ▸ | POLB | P06746 | 13/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.77 |
| ▸ | HPGD | P15428 | 9/20 | 0.77 |
| ▸ | PKM | P14618 | 8/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.77 |
| ▸ | LMNA | P02545 | 5/20 | 0.77 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.77 |
| ▸ | GLA | P06280 | 3/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.77 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.77 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.77 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 8/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 8/20 | 0.70 |
| ▸ | RECQL | P46063 | 2/20 | 0.70 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.70 |
| ▸ | PPARG | P37231 | 1/20 | 0.70 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29702983 | 1.00 | KAT8 (0.78) | KAT8POLBALDH1A1KDM4EHPGD | |
| SCHEMBL28514597 | 0.85 | KAT8 (0.80) | KAT8POLBALDH1A1KDM4EHPGD | |
| SCHEMBL29703004 | 0.85 | KAT8 (0.80) | KAT8POLBALDH1A1KDM4EHPGD | |
| SCHEMBL28525057 | 0.83 | KAT8 (0.76) | KAT8POLBALDH1A1KDM4EHPGD | |
| SCHEMBL29703050 | 0.83 | KAT8 (0.76) | KAT8POLBALDH1A1KDM4EHPGD | |
| SCHEMBL29703163 | 0.83 | KDM4E (1.00) | KAT8POLBALDH1A1KDM4EHPGD | |
| SCHEMBL13856164 | 0.83 | KDM4E (1.00) | KAT8POLBALDH1A1KDM4EHPGD | |
| SCHEMBL30544648 | 0.82 | RAB9A (0.76) | POLBALDH1A1KDM4EHPGDPKM | |
| SCHEMBL24688077 | 0.81 | POLB (0.86) | POLBALDH1A1KDM4EHPGDPKM | |
| SCHEMBL24688076 | 0.81 | POLB (0.82) | POLBALDH1A1KDM4EHPGDPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074880-A1 | NOVEL QUINOLINE DERIVATIVES AND USES THEREOF | ST EUROPEO DI ONCOLOGIA S R L (IT) | 2025-03-06 | — | — | US | disclosed |
| EP-4337640-A1 | NOVEL QUINOLINE DERIVATIVES AND USES THEREOF | Istituto Europeo di Oncologia S.r.l. (IT) | 2024-03-20 | — | — | EP | disclosed |
| WO-2022238863-A1 | NOVEL QUINOLINE DERIVATIVES AND USES THEREOF | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2022-11-17 | — | — | WO | disclosed |
| EP-4089077-A1 | NOVEL QUINOLINE DERIVATIVES AND USES THEREOF | Istituto Europeo di Oncologia S.r.l. (IT) | 2022-11-16 | — | — | EP | disclosed |
| CN-112321571-B | 2-furan-quinoline-4-formamide compound and application thereof | 浙江工业大学 | 2022-06-03 | — | — | CN | disclosed |
| CN-112920115-A | Quinoline-4-formamide skeleton derivative and application thereof | 四川大学 | 2021-06-08 | — | — | CN | disclosed |
| CN-112321571-A | 2-furan-quinoline-4-formamide compound and application thereof | 浙江工业大学 | 2021-02-05 | — | — | CN | disclosed |
| WO-2015106272-A1 | SMALL MOLECULE INHIBITORS OF APOBEC3G AND APOBEC3B | HARKI DANIEL A (US) | 2015-07-16 | — | — | WO | disclosed |
| US-20140275224-A1 | CYTOSINE DEAMINASE MODULATORS FOR ENHANCEMENT OF DNA TRANSFECTION | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275224-A1 | CYTOSINE DEAMINASE MODULATORS FOR ENHANCEMENT OF DNA TRANSFECTION | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275224-A1 | CYTOSINE DEAMINASE MODULATORS FOR ENHANCEMENT OF DNA TRANSFECTION | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2014-09-18 | — | — | US | disclosed |
| EP-2635280-A2 | CYTOSINE DEAMINASE MODULATORS FOR ENHANCEMENT OF DNA TRANSFECTION | Regents of the University of Minnesota (US) | 2013-09-11 | — | — | EP | disclosed |
| WO-2013074059-A2 | CYTOSINE DEAMINASE MODULATORS FOR ENHANCEMENT OF DNA TRANSFECTION | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2013-05-23 | — | — | WO | disclosed |
| WO-2013074059-A2 | CYTOSINE DEAMINASE MODULATORS FOR ENHANCEMENT OF DNA TRANSFECTION | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074880-A1 | NOVEL QUINOLINE DERIVATIVES AND USES THEREOF | NDC1, CHD1L, NUMA1 | KAT8 646/4885POLB 637/4885ALDH1A1 4197/4885 |
| US-20140275224-A1 | CYTOSINE DEAMINASE MODULATORS FOR ENHANCEMENT OF DNA TRANSFECTION | CDA, DCTD, ADA | KAT8 4393/4885POLB 108/4885ALDH1A1 2191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.